[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335864-105":59,"doc-detail-335864-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","overcoming-microbiome-acquired-gemcitabine-resistance-in-pancreatic-ductal-adenocarcinoma","Overcoming Microbiome-Acquired Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma","","Gastrointestinal cancers are among the most recurrent diseases worldwide, and pancreatic ductal adenocarcinoma (PDAC) accounts for 90–95% of pancreatic malignancies. Pancreatic cancer has a very poor prognosis due to nonspecific symptoms causing late diagnosis and, critically, rapid development of resistance to anticancer drugs. Gemcitabine is a standard PDAC treatment but resistance emerges quickly, while the microbiome has been recognized as a cancer hallmark that can promote drug resistance. This review summarizes existing evidence on how the microbiome shapes PDAC development through effects on the gemcitabine pathway, influencing gemcitabine response, with implications for more personalized therapeutic strategies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/overcoming-microbiome-acquired-gemcitabine-resistance-in-pancreatic-ductal-adenocarcinoma/335864/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/overcoming-microbiome-acquired-gemcitabine-resistance-in-pancreatic-ductal-adenocarcinoma/335864.png","ImageObject",300,407,{"name":92,"@type":93},"Logic","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is pancreatic ductal adenocarcinoma (PDAC) difficult to treat?","Question",{"text":112,"@type":113},"PDAC has a poor prognosis largely because symptoms are nonspecific, leading to late diagnosis, and because it develops high resistance to anticancer drugs.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How is gemcitabine related to PDAC therapy and resistance?",{"text":117,"@type":113},"Gemcitabine is a standard treatment for PDAC, but resistance to gemcitabine develops very fast, limiting long-term effectiveness.",{"name":119,"@type":110,"acceptedAnswer":120},"What role does the microbiome play in gemcitabine resistance according to the review?",{"text":121,"@type":113},"The microbiome is described as a cancer hallmark that can promote drug resistance, and the review focuses on how microbiome-driven effects may mold PDAC response through the gemcitabine pathway.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335864,1791144126,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},1099513958762,"https://ap-avatar.wpscdn.com/avatar/1000023916a998db790?x-image-process=image/resize,m_fixed,w_180,h_180&k=1784791008015729253","biomedicines  \nReview  \nOvercoming Microbiome-Acquired Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma  \nInês Mendes 1,2,3 and Nuno Vale 1,2,4, *  \nCitation: Mendes, I.; Vale, N. Overcoming Microbiome-Acquired Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma. Biomedicines 2024, 12, 227. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.3390/biomedicines12010227](10.3390/biomedicines12010227)  \nAcademic Editors: Manish Tripathi and Puneet Vij  \nReceived: 5 January 2024  \nRevised: 13 January 2024  \nAccepted: 17 January 2024  \nPublished: 19 January 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 PerMed Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Doutor Plácido da Costa, 4200-450 Porto, Portugal; [inesmendes_2000@hotmail.com](inesmendes_2000@hotmail.com)  \n2 CINTESIS@RISE, Faculty of Medicine, University of Porto, Alameda Professor Hernâni Monteiro, 4200-319 Porto, Portugal  \n3 School of Life and Environmental Sciences, University of Trás-os-Montes and Alto Douro (UTAD), Edifício de Geociências, 5000-801 Vila Real, Portugal  \n4 Department of Community Medicine, Information and Health Decision Sciences (MEDCIDS), Faculty of Medicine, University of Porto, Rua Doutor Plácido da Costa, 4200-450 Porto, Portugal  \n* [Correspondence: nunovale@med.up.pt](Correspondence: nunovale@med.up.pt); Tel.: +351-220426537  \nAbstract: Gastrointestinal cancers (GICs) are one of the most recurrent diseases in the world. Among all GICs, pancreatic cancer (PC) is one of the deadliest and continues to disrupt people’s lives worldwide. The most frequent pancreatic cancer type is pancreatic ductal adenocarcinoma (PDAC), representing 90 to 95% of all pancreatic malignancies. PC is one of the cancers with the worst prognoses due to its non-specific symptoms that lead to a late diagnosis, but also due to the high resistance it develops to anticancer drugs. Gemcitabine is a standard treatment option for PDAC, however, resistance to this anticancer drug develops very fast. The microbiome was recently classified as a cancer hallmark and has emerged in several studies detailing how it promotes drug resistance. However, this area of study still has seen very little development, and more answers will help in developing personalized medicine. PC is one of the cancers with the highest mortality rates; therefore, it is crucial to explore how the microbiome may mold the response to reference drugs used in PDAC, such as gemcitabine. In this article, we provide a review of what has already been investigated regarding the impact that the microbiome has on the development of PDAC in terms of its effect on the gemcitabine pathway, which may influence the response to gemcitabine. Therapeutic advances in this type of GIC could bring innovative solutions and more effective therapeutic strategies for other types of GIC, such as colorectal cancer (CRC), due to its close relation with the microbiome.  \nKeywords: drug resistance; genetic instability; gemcitabine pathways; microbiome-induced resistance; personalized medicine  \n1. Introduction  \nPancreatic cancer (PC) is in the list of the deadliest types of cancer. Pancreatic neoplasms are a critical and growing global public health problem, mainly due to the fact that epidemiological estimates for PC reveal that it is the seventh major cause of overall cancer mortality in nations with widely developed industries, as well as the third most frequent cause of mortality in the USA [1] .  \nPancreatic ductal adenocarcinoma (PDAC) is notably the most frequent pancreatic neoplastic cancer, being responsible for approximately 90 to 95% of all pancreatic ma","cbCaitASuygekctc","https://ap.wps.com/l/cbCaitASuygekctc","pdf",1236664,23,"English","# Introduction\n## Pancreatic ductal adenocarcinoma burden and prognosis\n## Treatment landscape and limitations\n# Microbiome and drug resistance (overview)","[{\"question\":\"Why is pancreatic ductal adenocarcinoma (PDAC) difficult to treat?\",\"answer\":\"PDAC has a poor prognosis largely because symptoms are nonspecific, leading to late diagnosis, and because it develops high resistance to anticancer drugs.\"},{\"question\":\"How is gemcitabine related to PDAC therapy and resistance?\",\"answer\":\"Gemcitabine is a standard treatment for PDAC, but resistance to gemcitabine develops very fast, limiting long-term effectiveness.\"},{\"question\":\"What role does the microbiome play in gemcitabine resistance according to the review?\",\"answer\":\"The microbiome is described as a cancer hallmark that can promote drug resistance, and the review focuses on how microbiome-driven effects may mold PDAC response through the gemcitabine pathway.\"}]","Overcoming Microbiome-Acquired Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma | PDF",1790012612,58]